{"id":251470,"date":"2021-09-15T00:00:00","date_gmt":"2021-09-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidcv0048-biopharma-venous-thromboembolism-epidemiology-middle\/"},"modified":"2026-03-31T10:42:32","modified_gmt":"2026-03-31T10:42:32","slug":"epidcv0048-biopharma-venous-thromboembolism-epidemiology-middle-east-africa","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcv0048-biopharma-venous-thromboembolism-epidemiology-middle-east-africa\/","title":{"rendered":"Venous Thromboembolism &#8211; Epidemiology &#8211; Middle East &#038; Africa"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of venous thromboembolism (<abbr data-abbreviation-entity=\"4992\" title=\"venous thromboembolism\">VTE<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of <abbr title=\"venous thromboembolism\">VTE<\/abbr> for each country, as well as annualized event counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan; we use 10 years for the rest of the countries.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr title=\"venous thromboembolism\">VTE<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all diagnosed <abbr title=\"venous thromboembolism\">VTE<\/abbr> events, how many in each country are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"venous thromboembolism\">VTE<\/abbr> over the forecast period?<\/li>\n<li>How will improvements in healthcare access and diagnostic technology affect the epidemiology of <abbr title=\"venous thromboembolism\">VTE<\/abbr> in the low-income countries over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology forecasts eight <abbr title=\"venous thromboembolism\">VTE<\/abbr> patient populations as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed <abbr title=\"venous thromboembolism\">VTE<\/abbr> events.<\/li>\n<li>Diagnosed <abbr title=\"deep vein thrombosis\">DVT<\/abbr> events.<\/li>\n<li>Diagnosed <abbr title=\"pulmonary embolism\">PE<\/abbr> events.<\/li>\n<li>Diagnosed <abbr title=\"deep vein thrombosis\">DVT<\/abbr> events by drug treatment.<\/li>\n<li>Diagnosed <abbr title=\"pulmonary embolism\">PE<\/abbr> events by drug treatment.<\/li>\n<li>Diagnosed <abbr title=\"venous thromboembolism\">VTE<\/abbr> events by etiology.<\/li>\n<li>Diagnosed <abbr title=\"venous thromboembolism\">VTE<\/abbr> events by cancer association.<\/li>\n<li>Diagnosed <abbr title=\"venous thromboembolism\">VTE<\/abbr> events by recurrence.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country and region.<\/p>\n","protected":false},"template":"","class_list":["post-251470","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-cardiovascular","biopharma-therapy-areas-venous-thromboembolism","biopharma-product-epidemiology","biopharma-geography-middle-east-africa","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251470","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251470\/revisions"}],"predecessor-version":[{"id":576376,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251470\/revisions\/576376"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251470"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}